{
"endpoint": "pubmed-search",
"count": 1,
"truncated": true,
"took_ms": 2850,
"items": [
{
"recordType": "paper",
"pmid": "41931049",
"title": "GLP-1 Receptor Agonists.",
"abstract": "Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety (which promotes weight loss). Beyond the impressive effects of GLP-1 receptor agonists on blood glucose levels and body weight, large-scale randomized, controlled trials have shown that GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes. Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass. Questions remain about long-term adherence, weight regain after discontinuation of treatment, and the functional implications of the loss of muscle and bone mass. Recent and ongoing targeted studies suggest the possibility of additional uses for GLP-1 receptor agonists.",
"authors": [
"Clifford J Rosen",
"Julie R Ingelfinger"
],
"authorCount": 2,
"firstAuthor": "Clifford J Rosen",
"journal": "The New England journal of medicine",
"journalAbbrev": "N Engl J Med",
"issn": "1533-4406",
"year": "2026",
"pubDate": "2026-04-02",
"volume": "394",
"issue": "13",
"pages": "1313-1324",
"pubTypes": [
"Journal Article",
"Review"
],
"meshTerms": [
"Humans",
"Cardiovascular Diseases",
"Diabetes Mellitus, Type 2",
"Glucagon-Like Peptide 1",
"Glucagon-Like Peptide-1 Receptor Agonists",
"Hypoglycemic Agents",
"Incretins",
"Obesity",
"Renal Insufficiency",
"Anti-Obesity Agents",
"Disease Progression",
"Gastric Emptying",
"Glucagon",
"Gastrointestinal Microbiome",
"Satiety Response",
"Randomized Controlled Trials as Topic",
"Medication Adherence"
],
"url": "https://pubmed.ncbi.nlm.nih.gov/41931049/",
"scrapedAt": "2026-11-11T16:06:22.336Z"
}
]
}
curl --location --request GET 'https://zylalabs.com/api/14840/pubmed+search+api/38492/search+pubmed+articles?query=GLP-1 obesity trial&sort=relevance&includeMesh=true&limit=2' --header 'Authorization: Bearer YOUR_API_KEY'
注册后,每个开发者都会被分配一个个人 API 访问密钥,这是一个唯一的字母和数字组合,用于访问我们的 API 端点。要使用 PubMed搜索 API 进行身份验证,只需在 Authorization 标头中包含您的 bearer token。
| 标头 | 描述 |
|---|---|
授权
|
必需
应为 Bearer access_key. 订阅后,请查看上方的"您的 API 访问密钥"。
|
搜索PubMed并获取带有PMID、摘要、作者、期刊、年份和MeSH术语的文章
每个响应都是包含计数、took_ms字段和准备存储或查询的扁平记录的项数组的JSON
不 请求在服务器端处理 你只需要发送你的API密钥和该端点中描述的参数
每次调用都会实时读取源数据,因此记录反映了请求时上游源的状态
您会收到一个明确的错误状态,而不是空结果,因此失败永远不会被误认为没有数据
是的,每个端点限制每个请求的记录数;最大值在限制参数中说明